Welcome to Bristol Myers Squibb Washington
Bristol Myers Squibb’s robust presence in Washington state is transforming the way difficult-to-treat cancers are approached.
Our teams in Seattle and Bothell discover, develop, manufacture and commercialize therapies in Immuno-Oncology (I-O) and cell therapy. Through continued leadership in the rapidly developing fields of engineered cell-based therapies and biotherapeutics aimed at harnessing the power of immune cells to enhance or restore the body’s ability to fight cancer, we seek to advance novel treatments for cancer patients with precision and purpose.
Meet our team
Learn about our leaders who are making a difference in Washington state.
Teresa (Teri) Foy, Ph.D., is an immunologist with more than 25 years of biotechnology and pharmaceutical industry experience developing novel therapeutics in the areas of oncology and inflammation.
Chris Holt leads the day-to-day operations of Bristol Myers Squibb’s Bothell site and oversees cell therapy manufacturing operations to deliver personalized (autologous) therapies to patients globally.
Doug Bassett leads a team of data scientists and analysts who harness the power of big data, artificial intelligence (AI) and machine learning in search of deeper insights into disease biology.
Justine Dell’Aringa is a director of Translational Medicine, working in Bristol Myers Squibb’s Immuno-Oncology and Cell Therapy Thematic Research Center.
Alison Fitch is director of scientific operations and strategy for the Immuno-Oncology and Cell Therapy (IO-CT) Thematic Research Center at Bristol Myers Squibb’s Seattle site.
Leanne Peiser, PhD, leads a team working on translational research evaluating cellular therapies and select immuno-oncology assets in clinical development in lymphoma, acute myeloid leukemia and solid tumors.
Pallavur (PV) Sivakumar, PhD, leads discovery efforts for the early immuno-oncology and cell therapy pipeline across all modalities to find the next innovative therapy for treating patients with various cancers.
Join us as we transform patient lives through science
Everyday, each of us work to improve outcomes of patients fighting serious diseases. Together we’re building a better future for each other and the patients who need us the most.
Driving innovation forward in Washington state
Learn about our broad scope of scientific innovation in Washington state.
Building on our legacy of pioneering transformational science, Bristol Myers Squibb is the first company with two approved chimeric antigen receptor (CAR) T cell therapies in hematologic malignancies with two distinct targets addressing separate blood cancers.
With multiple cell-based therapeutic approaches under investigation in blood cancers and beyond, Bristol Myers Squibb researchers like Justine Dell’Aringa are harnessing the immune system to reimagine the future of cancer treatment.
BMS is a leader in autologous chimeric antigen receptor (CAR) T cell therapy, a type of cancer immunotherapy where a patient’s own T cells are genetically engineered to recognize and bind to proteins found on the surface of certain cancer cells. This video, shared by the Discovery Research team of the Immuno-Oncology and Cell Therapy (IO-CT) thematic research center (TRC) in Seattle, Washington, shows a tumor cell being destroyed by CAR T cells.
Learn how we are making a difference in communities across Washington state.
Learn more about our scientific approaches and innovation.
Bristol Myers Squibb is advancing cell therapy research through novel manufacturing approaches and a well-established supply chain platform across a broad network of state-of-the-art facilities with cutting-edge technologies and highlight trained manufacturing teams.